In the post-genome era, technologies are becoming available that allow the pro®ling of tissues and cell populations at multiple levels including genomic (DNA and RNA), proteomic (proteins and peptides) and post-proteomic (eg metabolomic). Operomics refers to the molecular analysis of tissues and cells at the three levels that are connected through the coding process Ð namely, DNA, RNA and protein. The premise is that no one level or type of analysis fully captures gene expression and that functional changes at the proteome level cannot be simply predicted from analyses at the DNA or RNA levels. An important determinant that weakens a direct link between RNA and protein levels is translational control that differentially regulates mRNA translation. In this paper, the approaches for genomic and proteomic pro®ling and the contribution of translational control are reviewed.
INTRODUCTION
The successful completion of the human genome project, and the sequencing of other important genomes, has created a bonanza in the form of opportunities for new ways to study gene expression and for major new initiatives in the post-genome era. A case in point is proteomics, which is in an extraordinary growth phase. This is due, to a great extent, to the fact that the availability of a complete genome sequence for an organism provides a sequence-based framework for mining the proteome. A major distinctive feature between the genome and the proteome for higher organisms is that the genome sequence is relatively unidimensional and ®nite, whereas an organism's proteome is multidimensional, with quasi-in®nite dimensions stemming from the large number of cell lineages and subtypes, each with its own proteome although sharing the same genome. Given the dynamic nature of the proteome, constantly changing in response to various environmental factors and other signals, it follows that no cellular state(s) or experimental conditions could fully capture it.
In the post-genome era, there is a compelling need to extend knowledge of the human genome sequence to functional levels, through the comprehensive analysis of the different cellular and tissue constituents. Although expression analyses at the level of the transcriptome and proteome have generated substantial interest, numerous other`omes', as listed in Table 1 , are amenable to global pro®ling. This paper is focused particularly on aspects of molecular analyses of cells and tissues at the levels of the genome, transcriptome and proteome, encompassed in the term operome'. Unlike other`omes', these three`omes' are linked unidirectionally through the coding process. Outcomes of analyses at the three levels include: linking gene expression patterns to sequence variations or epigenomic changes; determining the interplay between regulatory controls that operate at the genomic, transcriptomic and proteomic levels; deciphering gene expression programmes across cell types, developmental stages and ageing; identifying previously unrecognised patterns of cellular responses to various signals; and deriving a better understanding of disease processes as well as novel predictive classi®cations of diseases based not only on genomic characteristics but also on their impact on the transcriptome and proteome.
The concept of the operome was ®rst introduced in a study of DNA methylation heterogeneity at the single cell level and of its impact on gene expression. 1 This concept emphasises that, while cells in a population may have inherited essentially the same genome from a nucleotide sequence point of view, operationally they may differ considerably in their genome, due to epigenetic modi®cations. As a result, substantial differences in gene expression between cells that are identical with respect to their DNA sequence are observed. Further, given the variable exposure of individual cells to exogenous factors and other stochastic processes, a marked heterogeneity among genetically identical cells would be expected in their transcriptome and proteome. The term operomics' encompasses the molecular analysis of cells and tissues at these three levels which, in combination, determine, control and/or regulate function.
GENOMIC PROFILING OF CELLS AND TISSUES
Several technologies are currently available for genome-wide scanning for somatic gains and losses at chromosomal and subchromosomal levels and for pro®ling genomic methylation, which is a major contributor to epigenetics. Whole genome approaches for detecting single nucleotide substitutions as may result from somatic mutations have remained rather elusive. Whereas genomic methylation patterns are relevant to numerous biological processes from development to ageing and disease, DNA sequence gains and losses are particularly relevant to cancer. Comparative genomic hybridisation (CGH) is a technique that has been utilised for the detection of chromosomal copy number changes in tumour tissue, without the need for culturing tumour cells. 2 It provides a global assessment in tumours of gains and losses in chromosomal regions throughout the whole genome. Tumour DNA is labelled with a¯uorochrome and mixed with normal DNA which is labelled with another¯uorochrome and hybridised to normal human metaphase preparations. The labelled normal and tumour DNAs compete for hybridisation to their locus of origin on the chromosomes. The ratios of two¯uorochromes provide a measure of gains and losses at speci®c chromosomal regions. CGH has been widely utilised to search for novel regions of ampli®cation or deletion. Systematic studies using CGH have shown, for example, that, in human solid tumours, numerous regions of ampli®cation encompassed ampli®ed genes not previously associated with cancer. 3 The resolution of CGH is limited to the level of chromosomal bands. Microarray-based CGH has been developed, in which¯uorescence ratios for spotted DNA elements provide a measure of DNA copy number in the genome for corresponding loci. Large genomic clones such as bacterial arti®cial chromosomes (BACs) have been utilised as array targets. 4 Alternatively, cDNAs have been utilised. 5 Analysis of DNA copy number variation using cDNA microarrays requires a high level of sensitivity of detection. Microarraybased approaches for genome scanning DNA methylation is a major contributor to epigenetics CGH allows scanning of the genome for gene copy changes While the above techniques provide a measure of genomic dosage changes at the level of chromosome bands for CGH and at the level of targeted DNA for microarrays, they do not allow assessment of genomic methylation changes. DNA methylation, as a somatic event, has the potential of diversifying gene expression in individual cells of the same lineage and methylation changes have been implicated in a number of diseases, including cancer. While programmed changes in DNA methylation occur during development and result in the establishment of tissuespeci®c DNA methylation patterns, 7 there is increasing evidence that ectopic changes in these methylation patterns may alter the expression of affected genes. 8 The technique of restriction landmark genomic scanning (RLGS) 9 allows the analysis of methylation changes as well as DNA copy number changes in the genome. With this technique, the use of a methylation-sensitive enzyme such as NotI to cut and end-label DNA fragments prior to their separation in two dimensions provides a quantitative assessment of methylation at NotI sites which characteristically occur in CpG islands. Several novel genes with altered copy number as well as methylation changes in different tumour types have been identi®ed by the authors' group using RLGS (Figure 1 ). 10±14 In a study of global methylation patterns of a large number of tumours using RLGS by another group, an estimated 600 CpG islands of the 45,000 in the genome were aberrantly methylated in tumours. Patterns of CpG island methylation were identi®ed that were shared within each tumour type, and other patterns were identi®ed that displayed distinct tumourtype speci®city. 15 It is clear at the present time, based on numerous genomic studies, that different tumour types or cancers at different stages of evolution show distinct patterns of gains and losses encompassing numerous chromosomes and chromosomal regions and substantial methylation changes. Yet the contribution of such relatively broad gains and losses to the modi®cation of gene expression has remained elusive. Thus, there is a need to determine the effect of various types of genomic changes from aneuploidy to speci®c chromosomal gains and losses, as well as methylation changes, on global gene expression. The need to integrate genomic data with gene
Restriction landmark genome scanning provides substantial sensitivity for gene copy changes involving CpG islands Figure 1 : RLGS patterns showing a CpG island fragment that is part of a chromosome 1q region that is ampli®ed in two glioma tumours (BT 26, BT 295), but not in a control. The CpG island is part of a novel gene designated`glioma ampli®ed gene' (GAC). Other intense fragments in the patterns are derived from rDNA genes, which occur in multiple copies in the genome expression data is not restricted to cancer, as, eventually, inherited polymorphisms affecting susceptibility to various diseases as well as epigenetic changes in the genome have to be ascertained with respect to their functional impact and effect on gene expression.
GLOBAL EXPRESSION PROFILING AT THE RNA LEVEL
Several technologies are currently available for pro®ling expression at the RNA level. Microarray technology is currently in wide use to analyse comparatively genome-wide patterns of mRNA expression, 16±20 the ultimate goal being to utilise arrays which contain every gene in a genome, against which mRNA expression levels can be quantitatively assessed. DNA microarrays provide an important new tool for the characterisation of tissues and cell lines. Large sets of genes involved in signal transduction, differentiation, apoptosis and cell cycle progression, could all be analysed simultaneously with respect to their expression. Microarray analysis exempli®es the type of comprehensive, large throughput technologies that may yield a molecular-based understanding of disease states. There is at present a substantial variety of arrays that may be utilised as well as choices of hardware, software and a variety of protocols for implementation. One technology for cDNA-based microarrays is based on an approach in which cDNA clone inserts are robotically printed onto glass slides and subsequently hybridised to two differentially¯uorescently labelled probes to compare the expression patterns of the cells from which they were derived. Another leading technology relies on the use of oligonucleotides. One concept that has been implemented involves the synthesis of tens of thousands of oligonucleotides onto the chips using photolithography, as developed by Affymetrix.
Most microarray-based studies of gene expression to date have followed an exploratory approach in which data generated at the RNA level for different samples have not been analysed in the context of changes at the genome or proteome levels. This is exempli®ed in a study by Golub et al. 21 in which oligonucleotide-based microarrays were used to analyse the RNA expression pro®les of acute leukaemias. A class discovery procedure they utilised automatically discovered the distinction between acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) without previous knowledge of these classes. An automatically derived class predictor was able to determine the class of new leukaemia cases. Using a procedure they developed that uses a ®xed subset of informative genes based on their correlation with the class distinction, 50 genes most closely correlated with the AML±ALL distinction in the known samples were relied on. A predictor was then used to classify new samples, by applying it to the expression levels of these genes in the sample.
Undoubtedly, global gene expression pro®ling at the RNA level, using approaches such as microarray analysis, will make signi®cant contributions to our understanding of normal and dysregulated gene expression programmes. From the functional point of view, the interpretation of RNA changes in the absence of other information, such as the levels of corresponding proteins, is rather dif®cult. This is simply illustrated by cases where RNA products for a given gene may be increased because of reduced levels of the corresponding protein and a consequent upregulation of RNA through feedback circuitry. Alternatively, increased RNA levels may translate into increased amount's of proteins. Which of the two scenarios is operable cannot be inferred simply from RNA levels. Given the potential for uncovering large numbers of genes that exhibit differential expression within any given study, there is a need for implementing ef®cient platforms for validation and for determining function in cellular contexts.
Virtually all genes in the human genome can be simultaneously assayed for their expression at the RNA level Ef®cient validation technologies have yet to be devised. Tissue microarrays have been utilised to determine expression of speci®c genes in large numbers of tissue sections. 22 Innovations for rapidly uncovering the function for large numbers of genes include microarraydriven gene expression systems. 23 Mammalian cells are cultured on a glass slide printed in de®ned locations with sets of complementary DNAs cloned in expression vectors. Cells growing on the printed areas take up the DNA creating spots of localised transfection within nontransfected cells that can be functionally assessed.
EXPRESSION PROFILING USING PROTEOMICS
Proteins are the most functional component encoded for in the genome. The large-scale pro®ling of gene expression at the protein level has a long history that predates pro®ling at the genomic and RNA levels. The ability to predict the sequences of all proteins in a species provides an important resource for protein expression studies that rely on protein separation technologies. During the lean years of proteomics, the ®eld was largely dominated by a single approach, namely two-dimensional (2D) gels. 24 With the heightened interest in the ®eld, the repertoire of technologies and resources available in proteomics has expanded and will likely further expand quite substantially in the near future. Mass spectrometry initially provided a shot in the arm to the 2D approach by substantially facilitating protein identi®cation, when combined with sequence database searching. Numerous optimisations have been introduced to facilitate identi®cation. For example, Brancia et al. 25 have increased the information produced from mass spectral analysis through the chemical derivatisation of tryptic peptides. In fact, the contributions of mass spectrometry to proteomics have extended beyond its synergism with 2D gels. 26 Mass spectrometry can be utilised for proteomic analysis in combination with separation technologies other than 2D gels. For example, Washburn et al. 27 
28±31
TRANSLATIONAL CONTROL: A LINK BETWEEN THE TRANSCRIPTOME AND THE PROTEOME Expression levels of a protein depend not only on transcription rates of the gene but also on additional mechanisms, including translational regulation. The regulation of protein levels by translational control has often been unappreciated. In recent years, interest in the mechanisms controlling the activity of the translation machinery has notably increased. Modulation of the initiation rate of protein synthesis can in¯uence both the overall rate of protein synthesis as well as the relative rates of synthesis of different proteins translated from different mRNA species which vary over a 100-fold range in their translation ef®ciency. 32, 33 Translation rates are increased in response to extracellular stimuli, but this increase is disproportionate; translation of some mRNAs is increased dramatically (up to 30-fold) while overall translational upregulation is modest (1.5-to two-fold). An increasing list of genes for which translational control plays an important role has accumulated. A good example of this translational control is the stimulation There is often discordance between expression at the RNA and protein levels for a given gene of ornithine decarboxylase synthesis in adipocytes in response to insulin. Most of the stimulation (ten-to 25-fold) is apparently at the level of translation, while only a two-to ®ve-fold increase is observed in transcriptional activation. The selective translational control can be dependent on mechanisms that target ligands to individual mRNAs, and on the differential sensitivity of mRNAs to subtle changes in the activity of components of the translation machinery. Several structural features in mRNAs, such as a complex 59 untranslated region (UTR) secondary structure and upstream open reading frames, have been found to contribute to the ef®ciency of translation initiation by eukaryotic ribosomes. 34 Scrutiny of vertebrate cDNA sequences in light of these criteria reveals a set of transcripts encoding oncoproteins, growth factors, transcription factors and cytokines that seem designed to be translated poorly. 35 Indeed, translational control has been well characterised for cyclin D, transforming growth factor and Fibroblast growth factor (FGF), 36±38 as well as for tumour necrosis factor-á, interferon and interleukin-2 genes.
39±44
A growing body of evidence links certain cancers to the altered translation of speci®c genes, such as reduced translation of a tumour suppressor gene, or to enhanced translation of a protooncogene. 45 Willis and co-workers ®rst demonstrated an aberrant translational control of the c-myc oncogene in multiple myeloma, leading to a ten-to 25-fold increase in the amount of c-myc protein. 46 They further observed a C-T mutation, present in 42 per cent of bone marrow samples obtained from patients with multiple myeloma and suf®cient to cause enhanced translation of c-myc. 47 A conserved mechanism for controlling the translation of â-F1-ATPase mRNA between the foetal liver and hepatocarcinoma cells was demonstrated. This mechanism involves translationinhibitory proteins that bind the 39-UTR of â-F1-ATPase mRNA. 48 Direct comparisons of mRNA and protein levels have been performed for one gene product in many cell types. 49 Interestingly, there was a poor correlation between mRNA and protein levels, which was even weaker in tumour cell lines. Indeed, several studies have demonstrated abnormal expression of translation factor mRNAs in malignant tissues.
The authors have performed a systematic comparison of the mRNA expression of a large set of translationrelated proteins in 220 human tumours, using oligonucleotide microarrays as designed by Affymetrix (unpublished data). The 220 human tumours consisted of 41 ovarian tumours, 57 lung carcinomas grades 1 and 3, 50 colon tumours, 24 oligodendrogliomas grades 3 and 2, 40 astrocytomas grades 4 and 1, and eight pancreatic tumours. Among the approximately 6,300 full-length human genes contained in the HuArray chips, 119 genes were selected that play a role in translation, including 23 initiation factors, six elongation factors, 79 ribosomal proteins and 11 regulators of translation factor activities. The data indicate that changes in expression levels in tumours are restricted to certain factors in a tumour-speci®c manner. For example, expression of the translation initiation factor eIF5A was strongly upregulated in pancreatic tumours as compared with normal pancreas and colon cancer. The poly(A)-binding protein, PABPC1, has been reported to modify translation ef®ciency. In lung tumours, PABPC1 was strongly overexpressed. In other studies, expression pro®les of colorectal cancer cells from eight tumours with corresponding non-cancerous colonic epithelia, using a DNA microarray consisting of 9,216 genes and including 4,220 genes of known function, identi®ed, among the 44 upregulated genes, the ribosomal proteins L8, L18, L18a, L29, L6, L3, L7, S5, S19 and eIF3-p110, and, among the 85 downregulated genes, eIF3-p36. 50 High expression of a very large group of ribosomal genes was also correlated with ovarian tumours that Translational control is an overlooked mechanism for regulating gene expression Genes involved in translational control are differentially expressed in cancer were histologically well differentiated, as compared with the most poorly differentiated tumours. 51 High expression of ribosomal proteins may, therefore, be correlated with less aggressive ovarian tumours.
Direct comparisons of mRNA and protein levels have also been performed for several genes in one tissue. 52 There was also, in this case, a poor correlation between mRNA and protein levels. Interestingly, microarray technology has been recently adapted for studies of translational control. 53±55 The methodology is based on the separation of polysomes from mRNPs using sucrose gradient centrifugation followed by oligonucleotide microarray hybridisation. It is based on the assumption that translationally inactive mRNAs are present as free cytoplasmic mRNPs, whereas actively translated mRNAs are contained within polysomes. This enables identi®cation of mRNAs speci®cally mobilised from cytoplasmic free mRNPs onto polysomes and vice versa. This type of analysis makes it possible to monitor simultaneously the translation state and level of individual mRNAs, using probes generated from mRNAs separated according to degree of ribosome loading, into well-translated and under-translated pools. This approach was shown to be an effective tool for superimposing translation pro®les on mRNA levels for large numbers of genes, as well as for identifying translationally regulated genes.
The authors recently applied this methodology to study translational control in immune cells. The data indicated that expression of a substantial proportion of genes is indeed controlled at the translation level. During differentiation of HL-60 cells into monocytes/macrophages induced by interferon treatment for ®ve days, approximately nine per cent of the expressed genes were observed to be transcriptionally regulated. Some of these genes were also regulated at the translation level, resulting, in most cases, in an accentuated effect on the expression of the gene. In addition, close to two per cent of the genes with unchanged transcript levels were translationally regulated with interferon-induced differentiation (Figure 2A) . Similarly, during differentiation of the HL-60 cells into granulocytes induced by Retinoic acid (RA) treatment for ®ve days, which resulted in dramatic phenotypic changes, approximately 22 per cent of the expressed genes were modulated at the transcript levels and that expression of close to seven per cent of the genes was subject to translational control ( Figure  2B ). Remarkably, in HL-60 cells as well as in Jurkat T cells, a large number of transcripts expressed in these cells are not translated. Therefore, the relevance of mRNA pro®ling data might be improved if the level of translational regulation is also taken into account and if direct assessment of protein levels can be determined.
INTEGRATED GENOMIC AND PROTEOMIC STUDIES OF GENE EXPRESSION
The comprehensive analysis of the genome, transcriptome and proteome of tissues is complicated by the substantial heterogeneity in cellular constituents. Although this problem is alleviated by analysing cells in culture, few studies to date have simultaneously analysed gene expression at the RNA and protein levels. An elegant study of the galactose utilisation pathway in yeast has integrated both RNA and protein analysis. 56 The effects of perturbations to critical components of this pathway were analysed using DNA microarrays, quantitative proteomics and databases of known physical interactions. Using this approach, 997 mRNAs were found to respond to 20 systematic perturbations of the galactose utilisation pathway. Approximately 15 of the 289 detected proteins were found to be regulated posttranscriptionally. The authors have utilised microarrays and proteomics to analyse the expression pro®le of human CD14(+) blood monocytes and their derived dentritic cells (DCs). 57 Analysis of gene expression changes at the RNA level using oligonucleotide microarrays complementary to 6,300 human genes showed that approximately 40 per cent of the genes were expressed in DCs. A total of 255 genes (four per cent) were found to be regulated during DC differentiation or maturation. Most of these genes were not previously associated with DCs and included genes encoding secreted proteins as well as genes involved in cell adhesion, signalling and lipid metabolism. Protein analysis of the same cell populations was done using 2D gel electrophoresis. A total of 900 distinct protein spots were included and four per cent of these exhibited quantitative changes during DC differentiation and maturation. Differentially expressed proteins were identi®ed by mass spectrometry and found to represent proteins with Ca 2 binding, fatty acid binding or chaperone activities, as well as proteins involved in cell motility. Although there was substantial concordance between protein levels and RNA levels, proteomic analysis provided an assessment of posttranslational modi®cations (Figure 3 ). For example, the chaperone protein calreticulin was found to undergo cleavage, yielding a novel form, a ®nding which obviously could not be predicted from RNA analysis. In another study of prostate cancer cells in culture, the authors have analysed gene expression changes induced by dihydrotestosterone (DHT) in the androgen-responsive prostate cancer line LNCaP, at both RNA and protein levels. 58 Changes at the RNA level induced by DHT were determined by means of serial analysis of gene expression (SAGE), and protein pro®ling was done by means of 2D gels. Among 123,371 transcripts analysed, a total of 28,844 distinct SAGE tags were identi®ed, representing 16,570 genes. Some 351 genes were signi®cantly affected by DHT treatment at the RNA level (p , 0.05), of which 147 were induced and 204 repressed by androgen. In two independent experiments, the integrated intensity of 32 protein spots increased and 12 decreased at least twofold in response to androgen, of a total of 1,031 protein spots analysed. The change in intensity for most of the affected proteins identi®ed could not be predicted based on the level of their corresponding RNA. Given the variable correlations between RNA and protein level, RNA:protein ratios may well represent a highly informative parameter that provides a meaningful measure of gene expression that varies between cellular states and between healthy and diseased cells and tissues. organising maps in which the number of nodes that serve as nucleation points for the genes clusters and their initial geometry in the space of the multiconditional expression intensities are ®xed. 65 Although approaches such as hierarchical clustering or Principal growth factor (PCA) likely contribute to our understanding of biological pathways, at the present time`directed' approaches to data analyses that address a speci®c question or hypothesis have been quite useful. For example, in ongoing studies of gene expression at the RNA and protein levels to derive information related to predicting survival in lung cancer, hierarchical clustering has proven to be of minimal utility. At the transcriptomic level, the authors analysed 86 tumours from newly diagnosed patients with lung adenocarcinoma for 6,800 genes using Affymetrix oligonucleotide microarrays. 67 The dataset was trimmed to remove genes that were either not expressed or only expressed at very low levels, which yielded a set of 4,966 genes for further analysis. Agglomerative hierarchical clustering of gene expression pro®les yielded three clusters of tumours that were minimally informative. One cluster differed signi®cantly with respect to histopathological differentiation. Among the 4,966 genes, 538 differed signi®cantly based on patient survival, 967 based on tumour stage and 1,994 based on tumour cluster (p < 0.05). Two independent statistical approaches were utilised to examine genes that may be predictive of patient survival. The ®rst utilised à training' set of 19 stage III tumours and à testing' set using 67 stage I tumours. The genes most signi®cantly associated with survival in the training set were used to identify a low-risk and a high-risk group among the stage I lung adenocarcinomas which differed signi®cantly with respect to survival (p 0.008). The second approach utilised`leave one out' crossvalidation analysis with all 86 tumour samples. An index based on expression of the genes most associated with survival among all 86 samples also identi®ed lowrisk and high-risk groups among the stage I lung adenocarcinomas, which differed signi®cantly with respect to survival (p 0.003). Although similar analyses at the protein level have also identi®ed a set of proteins that correlated with survival in lung cancer, an integrated approach to mining both RNA and protein expression may well identify interesting correlations between RNA and protein levels that have functional signi®cance.
It is clear that the volume of data to be collected, processed and mined at the genomic and proteomic levels to elucidate pathways and to determine function challenges the usual approaches to data handling and analysis and calls for new analytical tools. Novel approaches that have the potential to produce an integrated view of the cell's diverse programmes and pathways from data collected using various`omics' strategies are needed. Bioinformatics, a discipline which made initial headway through the implementation of computational tools for sequence analysis, is facing a much more daunting task to elucidate function, to unravel complex biological circuitry and to reverse engineer pathways, cellular programmes and disease pathogenesis. Integration of data across the different omes', together with other pertinent data, calls for new collaborations between computer scientists, statisticians and mathematicians on the one hand and biologists and clinical investigators on the other.
